{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T19:30:09Z","timestamp":1772220609955,"version":"3.50.1"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Senior Talent Startup Fund of Nanchang University","award":["28170120\/9167"],"award-info":[{"award-number":["28170120\/9167"]}]},{"name":"Postgraduate Innovation Special Fund of Jiangxi Province","award":["YC2023-S181"],"award-info":[{"award-number":["YC2023-S181"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Seasonal influenza vaccination is crucial for preventing influenza and its complications. Data from the United States Vaccine Adverse Event Reporting System (VAERS) indicate a higher proportion of adverse events (AEs) after influenza vaccination in hypertensive people. However, there is limited evidence on AEs in hypertensive people following seasonal influenza vaccination. We identified 4647 individuals aged 18 years or older with a history of hypertension who received seasonal influenza vaccination and 6380 seasonal influenza-vaccine-induced AEs between 1 January 2013 and 23 June 2023 from VAERS. We identified two groups for comparison: recovery and no recovery from seasonal influenza-vaccine-induced AEs. Propensity score matching (PSM) was performed to adjust for potential confounding factors, including demographic characteristics (age, sex, and region) and season of onset. Cox regression analysis was used to calculate the risk ratio of reported adverse events (AEs) that affected recovery after seasonal influenza vaccination. Most AEs were nonserious and occurred within 48 hours. The most common AEs were general disorders and administration site conditions (therapeutic and non-therapeutic responses, inflammation) and musculoskeletal and connective tissue disorders (musculoskeletal and connective tissue pain and discomfort, bursal disorders, joint-related signs, and symptoms). All three types of seasonal influenza vaccines were associated with injection site reactions (47.07% trivalent influenza vaccine [TIA], hazard ratio, HR 2.04, 95% confidence interval, CI 1.22\u20133.40; 20.00% quadrivalent influenza vaccine [QIA], HR 2.81, 95% CI, 1.81\u20134.37; 67.48% influenza vaccine, unknown manufacturer [FLUX], HR 2.83, 95% CI, 1.12\u20137.15) and were the AEs affecting the largest proportion of delayed recoveries in the hypertensive population. Potential AEs following seasonal influenza vaccination may affect the recovery of the hypertensive population. The majority of AEs reported were general disorders, predominantly injection site reactions, and nonserious.<\/jats:p>","DOI":"10.1371\/journal.pone.0310474","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T13:55:00Z","timestamp":1747749300000},"page":"e0310474","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse events affecting recovery from seasonal influenza vaccination in the hypertensive population: A population-based pharmacovigilance analysis"],"prefix":"10.1371","volume":"20","author":[{"given":"Hao","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaona","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8298-3415","authenticated-orcid":true,"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"pone.0310474.ref001","author":"World Health Organization"},{"issue":"9","key":"pone.0310474.ref002","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.tim.2018.05.013","article-title":"Influenza virus","volume":"26","author":"EC Hutchinson","year":"2018","journal-title":"Trends Microbiol"},{"issue":"1","key":"pone.0310474.ref003","article-title":"The Spanish influenza pandemic: a lesson from history 100 years after 1918","volume":"60","author":"M Martini","year":"2019","journal-title":"J Prev Med Hyg"},{"key":"pone.0310474.ref004","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3906\/sag-2004-133","article-title":"Understanding dynamics of pandemics","volume":"50","author":"L Akin","year":"2020","journal-title":"Turk J Med Sci"},{"issue":"1","key":"pone.0310474.ref005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/v15010116","article-title":"Influenza and universal vaccine research in China","volume":"15","author":"J Li","year":"2022","journal-title":"Viruses"},{"issue":"7","key":"pone.0310474.ref006","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz225","article-title":"Age-related differences in hospitalization rates, clinical presentation, and outcomes among older adults hospitalized with influenza-U.S. influenza hospitalization surveillance network (FluSurv-NET)","volume":"6","author":"CA Czaja","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"pone.0310474.ref007","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/M21-3668","article-title":"Characteristics and outcomes of hospitalized pregnant women with influenza, 2010 to 2019\u00a0: a repeated cross-sectional study","volume":"175","author":"R Holstein","year":"2022","journal-title":"Ann Intern Med"},{"issue":"2","key":"pone.0310474.ref008","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cid\/ciab931","article-title":"Vaccine effectiveness against life-threatening influenza illness in US children","volume":"75","author":"SM Olson","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pone.0310474.ref009","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.vaccine.2022.12.052","article-title":"Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza season","volume":"41","author":"KL Andrejko","year":"2023","journal-title":"Vaccine"},{"issue":"2","key":"pone.0310474.ref010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/vaccines6020019","article-title":"Efforts to improve the seasonal influenza vaccine","volume":"6","author":"AT Harding","year":"2018","journal-title":"Vaccines (Basel)"},{"issue":"14","key":"pone.0310474.ref011","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40265-013-0114-3","article-title":"Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix\u00ae quadrivalent): a review of its use in the prevention of disease caused by influenza A and B","volume":"73","author":"K McKeage","year":"2013","journal-title":"Drugs"},{"issue":"2","key":"pone.0310474.ref012","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/vaccines9020111","article-title":"Inclusion of safety-related issues in economic evaluations for seasonal influenza vaccines: a systematic review","volume":"9","author":"T Fens","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"29","key":"pone.0310474.ref013","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.vaccine.2016.05.018","article-title":"Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years","volume":"34","author":"EJ Asturias","year":"2016","journal-title":"Vaccine"},{"issue":"36","key":"pone.0310474.ref014","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"TT Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"pone.0310474.ref015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","volume":"23","author":"F Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"pone.0310474.ref016","volume-title":"Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification","author":"World Health Organization","year":"2019"},{"key":"pone.0310474.ref017","author":"World Health Organization"},{"key":"pone.0310474.ref018","doi-asserted-by":"crossref","first-page":"101410","DOI":"10.1016\/j.eclinm.2022.101410","article-title":"Economic evaluation of seasonal influenza vaccination in elderly and health workers: a systematic review and meta-analysis","volume":"47","author":"P Dilokthornsakul","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"1","key":"pone.0310474.ref019","first-page":"1","article-title":"Recommendations for influenza and Streptococcus pneumoniae vaccination in elderly people in China","volume":"3","author":"Recommendations for Influenza, Streptococcus pneumoniae Vaccination in Elderly People in China Writing Group, Geriatric Respiratory Group and Chinese Society of Geriatrics","year":"2020","journal-title":"Aging Med (Milton)"},{"issue":"5","key":"pone.0310474.ref020","article-title":"Influenza vaccines for preventing cardiovascular disease","volume":"2015","author":"C Clar","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pone.0310474.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.JAA.0000822520.39079.bd","article-title":"Recommended adult immunization schedule for ages 19 years or older: United States, 2022","volume":"35","year":"2022","journal-title":"JAAPA"},{"issue":"11","key":"pone.0310474.ref022","first-page":"1413","article-title":"Technical guidelines for seasonal influenza vaccination in China, 2018-2019","volume":"39","author":"LZ Feng","year":"2018","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"pone.0310474.ref023","author":"Centers for Disease Control and Prevention"},{"issue":"10","key":"pone.0310474.ref024","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/vaccines9101105","article-title":"Influenza vaccination coverage among older adults with hypertension in Shenzhen, China: a cross-sectional survey during the COVID-19 pandemic","volume":"9","author":"Q Li","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"48","key":"pone.0310474.ref025","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.1016\/j.vaccine.2018.10.045","article-title":"Influenza vaccination coverage of population and the factors influencing influenza vaccination in mainland China: A meta-analysis","volume":"36","author":"Q Wang","year":"2018","journal-title":"Vaccine"},{"key":"pone.0310474.ref026","author":"Centers for Disease Control and Prevention"},{"issue":"6","key":"pone.0310474.ref027","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41569-023-00964-1","article-title":"Immune and inflammatory mechanisms in hypertension","volume":"21","author":"TJ Guzik","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"36","key":"pone.0310474.ref028","article-title":"ATP release drives heightened immune responses associated with hypertension","volume":"4","author":"TV Zhao","year":"2019","journal-title":"Sci Immunol"},{"issue":"10","key":"pone.0310474.ref029","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.122.19694","article-title":"Hypertension and excess risk for severe COVID-19 illness despite booster vaccination","volume":"79","author":"JE Ebinger","year":"2022","journal-title":"Hypertension"},{"key":"pone.0310474.ref030","doi-asserted-by":"crossref","first-page":"665064","DOI":"10.3389\/fphys.2021.665064","article-title":"COVID-19 and Hypertension: The What, the Why, and the How","volume":"12","author":"S-A Muhamad","year":"2021","journal-title":"Front Physiol"},{"issue":"2","key":"pone.0310474.ref031","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5937\/hpimj1502266M","article-title":"Medical dictionary MedDRA: Used in over 60 countries, among which is Montenegro","volume":"2","author":"SS Mugosa","year":"2015","journal-title":"Hosp Pharm Int Multi J"},{"key":"pone.0310474.ref032","author":"MedDRA"},{"issue":"2","key":"pone.0310474.ref033","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"EG Brown","year":"1999","journal-title":"Drug Saf"},{"issue":"2","key":"pone.0310474.ref034","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/vaccines10020284","article-title":"Propensity-score-matched evaluation of adverse events affecting recovery after COVID-19 Vaccination: on adenovirus and mRNA vaccines","volume":"10","author":"C-S Son","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"pone.0310474.ref035","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3389\/fphar.2019.00973","article-title":"Propensity score methods in health technology assessment: principles, extended applications, and recent advances","volume":"10","author":"MS Ali","year":"2019","journal-title":"Front Pharmacol"},{"key":"pone.0310474.ref036","article-title":"Monitoring the safety of influenza A\/H1N1 pandemic and seasonal vaccines in Morocco","volume":"10","author":"A Tebaa","year":"2022","journal-title":"Ther Adv Vaccines Immunother"},{"key":"pone.0310474.ref037","doi-asserted-by":"crossref","DOI":"10.1590\/s1678-9946201961004","article-title":"Safety assessment of seasonal trivalent influenza vaccine produced by Instituto Butantan from 2013 to 2017","volume":"61","author":"VL Gatt\u00e1s","year":"2018","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"7","key":"pone.0310474.ref038","first-page":"262","article-title":"Association between seasonal influenza vaccines and the increased risk of acute disseminated encephalomyelitis, estimated using the Vaccine Adverse Event Reporting System","volume":"77","author":"M Fujimori","year":"2022","journal-title":"Pharmazie"},{"issue":"8","key":"pone.0310474.ref039","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/archdischild-2022-324269","article-title":"Association between maternal influenza vaccination and neurodevelopmental disorders in childhood: a longitudinal, population-based linked cohort study","volume":"108","author":"D Foo","year":"2023","journal-title":"Arch Dis Child"},{"issue":"4","key":"pone.0310474.ref040","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/gutjnl-2019-319300","article-title":"Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE\/APLAR\/APSDE\/APSH\/APSN\/PoA recommendations","volume":"69","author":"C-C Szeto","year":"2020","journal-title":"Gut"},{"key":"pone.0310474.ref041","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jconrel.2025.01.009","article-title":"Antigens and adjuvants co-stabilized Pickering emulsions amplify immune responses of subunit vaccines","volume":"379","author":"Z Guo","year":"2025","journal-title":"J Control Release"},{"issue":"7","key":"pone.0310474.ref042","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jamia\/ocab014","article-title":"Extracting postmarketing adverse events from safety reports in the vaccine adverse event reporting system (VAERS) using deep learning","volume":"28","author":"J Du","year":"2021","journal-title":"J Am Med Inform Assoc"},{"key":"pone.0310474.ref043","article-title":"Electronic Support for Public Health-Vaccine Adverse Event Reporting System (ESP:VAERS)-Final Report","volume-title":"(Prepared by Harvard Pilgrim Health Care, Inc. under Grant No. R18 HS017045)","author":"R Lazarus","year":"2010"},{"issue":"15","key":"pone.0310474.ref044","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings","volume":"385","author":"MG Thompson","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0310474.ref045","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.vaccine.2015.11.058","article-title":"The confounded effects of age and exposure history in response to influenza vaccination","volume":"34","author":"A Moster\u00edn H\u00f6pping","year":"2016","journal-title":"Vaccine"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T13:55:07Z","timestamp":1747749307000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310474"}},"subtitle":[],"editor":[{"given":"Omar Enzo","family":"Santangelo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0310474","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.03.24313030","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]}}}